Herbert Moessler
Tel Aviv University
57 Papers
244 Citations
Herbert Moessler is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Cerebrolysin & Randomized controlled trial. The author has an hindex of 21, co-authored 57 publications.
Chat about Author
Papers
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
Wolfgang Wrasidlo,Igor F. Tsigelny,Diana L. Price,Garima Dutta,Edward Rockenstein,Thomas C. Schwarz,Karin Ledolter,Douglas W. Bonhaus,Amy Paulino,Simona Eleuteri,Åge A. Skjevik,Åge A. Skjevik,Valentina L. Kouznetsova,Brian Spencer,Paula Desplats,Tania Gonzalez-Ruelas,Margarita Trejo-Morales,Cassia R. Overk,Stefan Winter,Chunni Zhu,Marie-Françoise Chesselet,Dieter Meier,Herbert Moessler,Robert Konrat,Eliezer Masliah +24 more
TL;DR: The notion that altering the interaction of α-synuclein with the membrane might be a feasible therapeutic approach for developing new disease-modifying treatments of Parkinson's disease and other synucleinopathies is supported.
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
Dafin F. Muresanu,Wolf-Dieter Heiss,Volker Hoemberg,Ovidiu Bajenaru,Christian Dinu Popescu,Johannes C. Vester,Volker W. Rahlfs,Edith Doppler,Dieter Meier,Herbert Moessler,Alla Guekht +10 more
TL;DR: Cerebrolysin had a beneficial effect on function and global outcome in early rehabilitation patients after stroke and its safety was comparable with that of the placebo, suggesting a favorable benefit/risk ratio.
114
Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease.
TL;DR: The association of apathy and APOE4 with reduced serum BDNF levels in AD is shown, and it is suggested that BDNF reductions might contribute to the worse cognitive performance exhibited by AD apathetic patients and femaleAPOE4 carriers.
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
TL;DR: The data indicate that the addition of Cerebrolysin significantly improved clinical outcome, and that the benefits persisted for at least 24 weeks.
62
Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.
Edward Rockenstein,Margaret Mallory,Michael Mante,M. Alford,Manfred Windisch,Herbert Moessler,Eliezer Masliah +6 more
TL;DR: Quantitative computer-aided analysis with anti-amyloid-beta protein (A beta) antibodies, revealed that Cerebrolysin significantly reduced the amyloid burden in the frontal cortex of 5-month-old mice, and Cere Brolysin treatment reduced the levels of A beta(1-42).
53